EP4570793A1 — 5-ht2a receptor inverse agonist, and preparation method therefor and use thereof
Assigned to Luye Innomind Pharma Shijiazhuang Co Ltd · Expires 2025-06-18 · 1y expired
What this patent protects
The present invention relates to a new compound as a 5-HT<sub>2A</sub> receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical composition in the p…
USPTO Abstract
The present invention relates to a new compound as a 5-HT<sub>2A</sub> receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical composition in the preparation of a drug for treating 5-HT<sub>2A</sub> receptor-related diseases. The diseases include non-motor symptoms caused by Parkinson's disease: delusions, hallucination, depression, anxiety, cognitive impairment and sleep disorders; dementia-related mental diseases; severe depression; or negative symptoms of schizophrenia, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.